In summary, we here describe the generation and characterization of an anti–Plexin-B1 antibody that specifically interferes with binding of Plexin-B1 to its high-affinity ligand, Sema4D, and validate its therapeutic efficacy in preclinical mouse models of osteoporosis and MS. Here, PLXNB1 is linked to myeloid sarcoma.